What Xenon Pharmaceuticals (XENE)'s Positive Phase 3 X-TOLE2 Epilepsy Data Means For Shareholders

Simply Wall St.04-22 14:06

Xenon Pharmaceuticals recently presented positive Phase 3 X-TOLE2 data at the American Academy of Neurology 2026 meeting, showing azetukalner meaningfully reduced focal onset seizure frequency versus ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629109209?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-22 14:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629109209","market":"hk","top_or_hot":-1,"title":"What Xenon Pharmaceuticals (XENE)'s Positive Phase 3 X-TOLE2 Epilepsy Data Means For Shareholders","media":"Simply Wall St.","content":"<div>\n<p>Xenon Pharmaceuticals recently presented positive Phase 3 X-TOLE2 data at the American Academy of Neurology 2026 meeting, showing azetukalner meaningfully reduced focal onset seizure frequency versus ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/what-xenon-pharmaceuticals-xenes-positive-phase-3-x-tole2-ep\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Xenon Pharmaceuticals (XENE)'s Positive Phase 3 X-TOLE2 Epilepsy Data Means For Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Xenon Pharmaceuticals (XENE)'s Positive Phase 3 X-TOLE2 Epilepsy Data Means For Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-22 14:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/what-xenon-pharmaceuticals-xenes-positive-phase-3-x-tole2-ep><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Xenon Pharmaceuticals recently presented positive Phase 3 X-TOLE2 data at the American Academy of Neurology 2026 meeting, showing azetukalner meaningfully reduced focal onset seizure frequency versus ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/what-xenon-pharmaceuticals-xenes-positive-phase-3-x-tole2-ep\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SOCL","symbol_name":"社交媒体ETF-Global X","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/what-xenon-pharmaceuticals-xenes-positive-phase-3-x-tole2-ep","article_id":"2629109209","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/what-xenon-pharmaceuticals-xenes-positive-phase-3-x-tole2-ep","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629109209","pubTimestamp":1776837979,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Xenon Pharmaceuticals recently presented positive Phase 3 X-TOLE2 data at the American Academy of Neurology 2026 meeting, showing azetukalner meaningfully reduced focal onset seizure frequency versus placebo in highly treatment-resistant adult patients.\nMulti-year open-label extension results and real-world survey data highlight azetukalner’s long-term seizure control and the potential practical benefit of a once-daily, no-titration epilepsy therapy for both patients and physicians.\nWith...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SOCL":"社交媒体ETF-Global X","XENE":"Xenon制药"},"translate_title":"Xenon Pharmaceuticals(XENE)积极的3期X-TOLE2癫痫数据对股东意味着什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SOCL":1.5,"XENE":1.5},"content_text":"Xenon Pharmaceuticals recently presented positive Phase 3 X-TOLE2 data at the American Academy of Neurology 2026 meeting, showing azetukalner meaningfully reduced focal onset seizure frequency versus placebo in highly treatment-resistant adult patients. Multi-year open-label extension results and real-world survey data highlight azetukalner’s long-term seizure control and the potential practical benefit of a once-daily, no-titration epilepsy therapy for both patients and physicians. With these new Phase 3 data and long-term extension results in hand, we’ll now examine how they may reshape Xenon’s investment narrative. We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementXenon Pharmaceuticals Investment Narrative RecapTo own Xenon, you need to believe azetukalner can become a meaningful new option across epilepsy and, over time, mood disorders, turning deep R&D spend into durable revenue. The new X‑TOLE2 Phase 3 and 48‑month extension data directly reinforce the core near term catalyst around an epilepsy filing, while the biggest risk still sits with future late stage or real world safety and efficacy holding up as exposure grows. Among recent corporate updates, Xenon’s plan to submit an NDA for azetukalner in Q3 2026 ties most closely to the new AAN data, since regulatory review and eventual launch readiness are now front and center for the stock’s catalyst path, even as the company continues to operate at a sizable net loss of US$345.91 million in 2025 and relies on capital markets to fund development. Yet while the Phase 3 data look encouraging, investors should still be aware that late stage dependence on a single asset means any safety issue or regulatory delay could... Read the full narrative on Xenon Pharmaceuticals (it's free!)Xenon Pharmaceuticals' narrative projects $284.9 million revenue and $45.7 million earnings by 2028. This requires 236.2% yearly revenue growth and a $352.0 million earnings increase from $-306.3 million today.Uncover how Xenon Pharmaceuticals' forecasts yield a $55.40 fair value, in line with its current price.Exploring Other PerspectivesXENE 1-Year Stock Price Chart Before this news, the most optimistic analysts were penciling in about US$905.1 million of 2029 revenue and a slim US$18.3 million profit, so X‑TOLE2’s success could either support that upbeat view or highlight how much must still go right for such aggressive assumptions to hold.Explore 4 other fair value estimates on Xenon Pharmaceuticals - why the stock might be worth over 5x more than the current price!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Xenon Pharmaceuticals research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.Our free Xenon Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xenon Pharmaceuticals' overall financial health at a glance.No Opportunity In Xenon Pharmaceuticals?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.Find 58 companies with promising cash flow potential yet trading below their fair value.AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629109209","isCrawlerRequest":true}